Tesamorelin vs Matrixyl
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →Matrixyl
Matrixyl (Palmitoyl Pentapeptide-4) is a signal peptide that stimulates collagen and extracellular matrix production. It is one of the most well-studied anti-aging peptides with proven efficacy for wrinkle reduction.
Full details →Side-by-Side Comparison
| Aspect | Tesamorelin | Matrixyl |
|---|---|---|
| Mechanism | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. | Mimics collagen breakdown fragments, triggering fibroblasts to produce new collagen, elastin, and other matrix components. Essentially tricks skin into repair mode without actual damage. |
| Typical Dosage | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. | Topical: 2-8% concentration in serums and creams. Matrixyl 3000 combines it with Palmitoyl Tetrapeptide-7 for enhanced effects. |
| Administration | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. | Topical application 1-2 times daily. Can be combined with other actives like retinol, vitamin C, and other peptides. |
| Side Effects | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. | Very well-tolerated. Rare mild irritation. Suitable for sensitive skin types. |
| Best For |
What They Have in Common
Both Tesamorelin and Matrixyl are commonly used for: